GLP-1 Receptor Agonists: Balancing Benefits and Risks in Treatment Decisions

By João L. Carapinha

January 13, 2025

A recent study highlighted several key points on the benefits and risks associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the importance of individualized treatment decisions. The risks of GLP-1RAs, especially their association with thyroid cancer, must be carefully evaluated while prescribing these medications. We’re highlighting this risk particularly given our Thyroid Awareness activities this month.

Increased Risk of Thyroid Cancer

The study clearly indicates that GLP-1RAs are associated with an increased risk of thyroid cancer. Specifically, the meta-analysis found that GLP-1RA treatment was linked to a higher risk of thyroid cancer when compared to other treatments. These other treatments included sodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase 4 inhibitors (DPP4i), as well as placebo. The odds ratio (OR) for thyroid cancer with GLP-1RA use was 1.58 (95% CI, 1.01 to 2.49).

Other Safety Concerns

In addition to the increased risk of thyroid cancer, the study noted other potential safety concerns associated with GLP-1RA use:

Suicidal Risk. GLP-1RAs were linked to a higher risk of suicide compared to DPP4is, though this finding is controversial and requires further investigation.
Macrovascular and Microvascular Outcomes. While GLP-1RAs showed benefits in reducing major adverse cardiovascular events (MACE) and stroke, they had a higher risk of hospitalization for heart failure (HHF) compared to SGLT2is.

Individualized Treatment Decisions

Given the distinct benefit-risk profiles of GLP-1RAs, SGLT2is, and DPP4is, the study emphasizes the importance of individualizing treatment decisions based on patient characteristics and risk factors. This includes considering:
Cardiovascular Risk Profile. GLP-1RAs are beneficial for reducing MACE and stroke but may have a higher risk of HHF compared to SGLT2is.
Renal Function. SGLT2is are favorable for reducing composite renal outcomes and hospitalization for heart failure.
Potential Adverse Effects. The risk of thyroid cancer, suicidal ideation, and other adverse effects should be carefully weighed against the benefits of GLP-1RA therapy.
Comorbidities and Priorities. Treatment choices must be tailored to each patient’s unique health profile, considering their primary health concerns and priorities.

In conclusion, while GLP-1RAs provide significant benefits in managing type 2 diabetes and associated cardiovascular risks, they also increase the risk of thyroid cancer and other adverse effects. Thus, individual risk factors should be meticulously considered when initiating GLP-1RA therapy to ensure optimal outcomes for each patient. Effective management hinges on understanding both the benefits and risks of GLP-1RAs.

Reference url

Recent Posts

Evolving Burden of Obesity in the US: Key Insights on Obesity Prevention Strategies

By HEOR Staff Writer

October 10, 2025

What are the most effective obesity prevention strategies for reducing long-term healthcare and societal costs in the United States? Recent advanced population models reveal that focusing on early, targeted obesity prevention strategies offers far greater value to health systems and society than ...
Simponi Pediatric Approval: FDA Grants First Pediatric Indication for Ulcerative Colitis Treatment

By HEOR Staff Writer

October 9, 2025

The U.S. Food and Drug Administration has granted Simponi pediatric approval for Johnson & Johnson's Simponi (golimumab), which is intended for children with moderately to severely active ulcerative colitis who weigh at least 15 kg. This historic approval is backed by data from the PURSUIT pr...
Paving the Way for Digital Health Technologies: NICE’s Bold New Strategy for the NHS
The National Institute for Health and Care Excellence (NICE) is expanding its technology appraisals programme, and starting April 2026, this will include digital health technologies that are placed on an equal legal footing with medicines in the NHS. This initiative forms part of the NHS 10-year ...